◆ 会议时间：2024年3月15-16日
◆ 会议地点：日本 京都

◆ 会议简介：

2024年第3届骨髓增生异常综合征区域研讨会(MDSR)将于2024年3月15-16日在日本京都举行，会议由骨髓增生异常综合征基金会(MDSF)主办。本次研讨会将从基础、转化和临床三个方面讨论MDS领域的热点问题；同前几次区域专题讨论会一样，主要讲座将由该领域公认的国际专家主讲，同时也期待着从全球同行提交的摘要中选出高水平的研究报告。MDS是一个以交流骨髓增生异常综合征知识为宣共同目标的国际医学专业人士社区。本次研讨会将为展示MDS领域的最新科学进展提供一个机会，同时也将为MDS社区的连接和协作提供一个机会。未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com)

MDSR 2024 - The 3rd Regional Symposium on Myelodysplastic Syndromes
Date: 15-16 March 2024,
Venue: ICC Kyoto, Tyoto, Japan

摘要征集：

Abstract submission deadline: Wednesday, November 29, 2023 (midnight GMT)

SUBMIT HERE点此提交

Rules for submission

Please read the submission rules before submitting an abstract.

• Abstracts must be submitted online via the website only. Abstracts submitted by email will not be accepted.
• Presentation Type: Abstracts may be submitted only for Poster viewing presentation.
• The Scientific Committee will determine whether the abstract will be accepted for presentation, with consideration given to the author’s preference.
• Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
• The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
• Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees by January 31, 2024 will be scheduled for presentation and included for publication.
• Submission of an abstract acknowledges your acceptance for the abstract to be published in the official Symposium publications.
• Abstracts must be original and must not have been published or presented at any other meeting prior to the 3rd Regional Symposium on Myelodysplastic Syndromes 2024.
• Abstracts must be submitted in English. All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.

Guidelines for submission

Before you begin, please prepare the following information:

1. Presenting author’s contact details:
   • Full first and family name(s)
   • Email address
   • Affiliation details: department, institution / hospital, city, state (if relevant), country
   • Phone number
2. Author and co-authors’ details.
3. Preferred Presentation type: Poster viewing. ​
4. Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words.
5. Abstract text - limited to 250 words including acknowledgements. Please note: word count is affected when tables are included.
6. Abstract topic – select the abstract topic per the list of topics.
7. Images – The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, GIF or PNG format.
8. Abstracts should clearly state:
   • Introduction
   • Methods
   • Results
   • Conclusions
9. Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
10. Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
11. Submissions may not contain patient names, hospital ID numbers or other identifying information.
12. The submission form allows you to store your abstract as a DRAFT until the deadline. After the deadline if not submitted, drafts will be deleted.
13. Click on the SUBMIT button at the end of the process in order to submit your abstract. You can make changes to your submitted abstract by the deadline. After the submission deadline abstracts cannot be modified or corrected.
    You will receive an abstract ID number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
    
14. Please do not submit multiple copies of the same abstract.

Abstract submitters’ declaration

• I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.
• Submission of the abstract constitutes my consent to publication (e.g. Symposium website, programs, other promotions, etc.).
• The Abstract Submitter warrants and represents that he/she is the sole owner or has the rights of all the information and content (“Content”) provided to MDSR 2024 and Kenes International (Hereafter: “The Organizers”). The publication of the abstract does not infringe any third party rights including, but not limited to, intellectual property rights.
• The Abstract Submitter grants the Organizers a royalty-free, perpetual, irrevocable nonexclusive license to use, reproduce, publish, translate, distribute, and display the content.
• The Organizers reserve the right to remove from any publication an abstract which does not comply with the above.
• I understand that I must select a specific Topic for my abstract allocation. Although the Scientific Committee will work hard to honour this selection, this cannot be guaranteed. The Scientific Committee reserves the right to change the Topic or Sub-Topic under which the abstract was originally submitted.
• I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.
• I understand that the presenting author must be a registered participant.
• I confirm to have received the consent of all authors for the processing of their contact details by Kenes and the Organizers.

Welcome Message

On behalf of the Local Organizing Committee and the MDS Foundation, it is our pleasure to invite you to the 3rd Regional Symposium on Myelodysplastic Syndromes which will be held in Kyoto, Japan, on 15-16 March 2024.

This regional symposium will cover hot topics in MDS, from basic, translational and clinical point of view. As in the previous regional symposiums, the main lectures will be delivered by recognized international leaders in the field. We will accept abstracts from the participants, and we would like to include research presentations from the submitted abstracts.

Please join us for a face-to-face meeting in Kyoto, a city of long-lasting history and authentic Japanese culture. Attendees will enjoy the direct interactive discussion with many hematologists, including leading MDS specialists, and Kyoto itself that is filled with historical monuments, and national treasures.

We hope you will enjoy “in-person” opportunities for MDS in Kyoto.

We look forward to meeting you.

Prof. Seishi Ogawa
Symposium Co-Chair

Dr. Yasushi Miyazaki
Symposium Co-Chair

注册费：

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。